Loading...
Market
What type of deal will Recursion Pharmaceuticals enter by end of 2024?
3
Resolution / Starting Odds
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Official announcements from Recursion Pharmaceuticals or partnering/acquiring company
Story
Recursion's First-in-Disease Drug REC-994 Meets Safety Endpoint, Efficacy Mixed in Phase 2 Study
Sep 3, 2024, 12:12 PM
Recursion Pharmaceuticals has announced the Phase 2 data for REC-994, its first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The AI-derived drug candidate met its primary endpoint of safety and tolerability in the mid-stage study. However, the efficacy results were mixed, with magnetic resonance imaging-based secondary endpoints showing a trend towards reduced lesion volume but not achieving significant efficacy. While the topline results are positive, they may not fully satisfy investors closely monitoring the AI drug developer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%